NCT00710359

Brief Summary

During fetal life and infancy, an adequate cobalamin status is important for normal growth and central nervous system development. During the last years we have detected cobalamin deficiency in a number of infants admitted to the Pediatric Department with various symptoms, including neurological symptoms and feeding problems. Cobalamin treatment is given to the infants with biochemical cobalamin deficiency, and leads to loss of symptoms and in improved physical condition. In this study we want to establish the prevalence of cobalamin deficiency in infants with gastrointestinal symptoms and/or feeding problems. Cobalamin status will be investigated in all children aged 8 months and younger, admitted to the Pediatric Department with these symptoms. In a randomised intervention trial we will evaluate the effect of cobalamin supplementation in children with these symptoms and metabolic evidence of impaired cobalamin status. Study hypothesis: Cobalamin treatment given to the infants with biochemical cobalamin deficiency, will lead to loss of symptoms and in improved physical condition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2008

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 2, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 4, 2008

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

August 16, 2010

Status Verified

August 1, 2010

Enrollment Period

2.3 years

First QC Date

July 2, 2008

Last Update Submit

August 13, 2010

Conditions

Keywords

Cobalamin deficiencyInfantNutritionCobalamin supplementationFeeding problemsGastrointestinal symptoms

Outcome Measures

Primary Outcomes (1)

  • Outcome Measure: Changes in cobalamin and folate status, including metabolic markers, hematological parameters, growth parameters, symptom and neurological evaluation

    Reevalutation after 4 weeks

Secondary Outcomes (1)

  • Maternal evaluation of changes in infant behaviour and symptoms

    After 4 weeks

Study Arms (2)

1

ACTIVE COMPARATOR

400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.

Dietary Supplement: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)

2

SHAM COMPARATOR

The controls receive an intramuscular "injection", however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance.

Dietary Supplement: Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)

Interventions

400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection

Also known as: Vitamin B12, Cobalamin, B vitamins
12

Eligibility Criteria

AgeUp to 8 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children below 8 months of age
  • Clinical diagnosis or symptoms: feeding problems and/or gastrointestinal symptoms

You may not qualify if:

  • Children with syndromic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Pediatrics, Haukeland University Hospital

Bergen, 5021, Norway

Location

Related Publications (6)

  • Rosenblatt DS, Whitehead VM. Cobalamin and folate deficiency: acquired and hereditary disorders in children. Semin Hematol. 1999 Jan;36(1):19-34.

    PMID: 9930566BACKGROUND
  • Bjorke Monsen AL, Ueland PM, Vollset SE, Guttormsen AB, Markestad T, Solheim E, Refsum H. Determinants of cobalamin status in newborns. Pediatrics. 2001 Sep;108(3):624-30. doi: 10.1542/peds.108.3.624.

    PMID: 11533328BACKGROUND
  • Wulffraat NM, De Schryver J, Bruin M, Pinxteren-Nagler E, van Dijken PJ. Failure to thrive is an early symptom of the imerslund Grasbeck syndrome. Am J Pediatr Hematol Oncol. 1994 May;16(2):177-80.

    PMID: 8166372BACKGROUND
  • Monsen AL, Refsum H, Markestad T, Ueland PM. Cobalamin status and its biochemical markers methylmalonic acid and homocysteine in different age groups from 4 days to 19 years. Clin Chem. 2003 Dec;49(12):2067-75. doi: 10.1373/clinchem.2003.019869.

    PMID: 14633879BACKGROUND
  • Bjorke-Monsen AL, Torsvik I, Saetran H, Markestad T, Ueland PM. Common metabolic profile in infants indicating impaired cobalamin status responds to cobalamin supplementation. Pediatrics. 2008 Jul;122(1):83-91. doi: 10.1542/peds.2007-2716.

    PMID: 18595990BACKGROUND
  • Torsvik I, Ueland PM, Markestad T, Bjorke-Monsen AL. Cobalamin supplementation improves motor development and regurgitations in infants: results from a randomized intervention study. Am J Clin Nutr. 2013 Nov;98(5):1233-40. doi: 10.3945/ajcn.113.061549. Epub 2013 Sep 11.

MeSH Terms

Conditions

Vitamin B 12 Deficiency

Interventions

HydroxocobalaminVitamin B 12Vitamin B Complex

Condition Hierarchy (Ancestors)

Vitamin B DeficiencyAvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CorrinoidsTetrapyrrolesPyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingMacrocyclic CompoundsPolycyclic CompoundsVitaminsMicronutrientsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and Uses

Study Officials

  • Anne-Lise Bjørke Monsen, M.D., Ph.D.

    Laboratory of Clinical Biochemistry, Haukeland University Hospital, N-5021 Bergen, Norway

    PRINCIPAL INVESTIGATOR
  • Per Magne Ueland, M.D., Ph.D.

    Department of Internal Medicine, University of Bergen, 5021 Armauer Hanssen Hus, Bergen, NORWAY

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 2, 2008

First Posted

July 4, 2008

Study Start

April 1, 2008

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

August 16, 2010

Record last verified: 2010-08

Locations